Dy­nacure se­cures $55M as their Io­n­is-de­vel­oped drug moves in­to clin­ic

A month af­ter dos­ing their first ever pa­tient with their Io­n­is-li­censed tech, Dy­nacure has an­nounced a new round of fund­ing to ad­vance the tri­al. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.